The hot flashes and night sweats that plague breast cancer survivors during years-long hormone-suppressing therapy are eased ...

After reporting a 15% sequential decline in Izervay sales for the opening quarter of this year, Astellas has reversed the ...

India's Glenmark Pharmaceuticals said on Thursday its innovation arm, Ichnos Glenmark Innovation (IGI), and AbbVie have ...

Pfizer (PFE) stock in focus as the company with Astellas Pharma (ALPMF) (ALPMY) announce a Phase 3 trial win for their ...

Good morning, we have news of a big M&A deal this morning. Let’s get into it. Merck said this moring that it will buy Verona ...

Recruitment initiated into the Phase 2 opaganib plus darolutamide study in patients with advanced prostate cancer, sponsored ...

The Global Fibromyalgia Treatment Market is expected to reach at a CAGR of 4.2 % during the forecast period 2025-2033. The ...

Review the current valuation for Astellas Pharma Inc ADR (ALPMY:PINX) stock based on a yearly calendar providing PE ratios, cash flow, EBITDA and other company valuation information.

Learn about the executive team and board of directors at Astellas Pharma Inc (ALPMF:PINX) and review their bios and compensation over the latest fiscal years.

The global retinitis pigmentosa market, valued at $11.31 billion in 2024, is expected to grow to $25.87 billion by 2034, driven by gene therapy advancements, aging populations, and strategic ...

XTANDI is the first and only androgen receptor pathway inhibitor (ARPI) indicated and reimbursed in Ontario for use in patients with nmCSPC with biochemical recurrence at high risk for metastasis ...

TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME ...